

## MediGene to Present at the Piper Jaffray Conference in London

Internet live webcast available at [www.medigene.com](http://www.medigene.com) from June 24, 2008

**Martinsried/Munich, June 20, 2008.** The biotech company MediGene AG (Frankfurt, Prime Standard: MDG) will give a presentation at the Piper Jaffray Conference in London. The speech will be made by Dr. Thomas Klaue, Chief Financial Officer of MediGene AG, on June 24, 2008 at 9:00 a.m. local time (10:00 CET). Dr. Klaue will give a business summary and update the audience on the latest business developments. The presentation will be webcast on the internet, and will be available from June 24 at [www.medigene.com](http://www.medigene.com).

MediGene possesses an attractive drug pipeline with two drugs on the market (Eligard<sup>®</sup> and Veregen<sup>®</sup>). Another drug (Oracea<sup>®</sup>) has already been recommended by the EMEA for approval. In the field of research & development, MediGene focuses primarily on its major projects EndoTAG<sup>™</sup>-1 und RhuDex<sup>™</sup>. These two candidates have an estimated maximum sales potential of more than 1 billion Euros annually. The drug candidate RhuDex<sup>™</sup> is developed as the first orally available CD80 interactor for the treatment of rheumatoid arthritis. EndoTAG<sup>™</sup>-1 is geared towards starving out tumor cells and could be suited for the treatment of numerous types of solid tumors. The underlying EndoTAG<sup>™</sup> technology shall provide a basis for other drugs. Due to the convincing clinical data obtained with the drug candidate EndoTAG<sup>™</sup>-1 for the treatment of pancreatic cancer, MediGene recently decided to focus its business strategy. All research and development activities as well as the planned sales and marketing activities of the company will be focused exclusively on the two areas oncology and immunology.

*This press release contains forward-looking statements representing the opinion of MediGene as of the date of this release. The actual results achieved by MediGene may differ significantly from the statements made herein. MediGene is not bound to update any of these forward-looking statements. EndoTAG<sup>™</sup>, EndoTAG<sup>™</sup>-1, Veregen<sup>®</sup> and MediGene<sup>®</sup> are trademarks of MediGene AG, RhuDex<sup>™</sup> is a trademark of MediGene Ltd. Oracea<sup>®</sup> is a registered trademark of CollaGenex Pharmaceuticals, Inc. These trademarks may be owned or licensed in select locations only.*

- ends -

**MediGene AG** is a publicly quoted (Frankfurt, Prime Standard: MDG) biotechnology company located in Martinsried/Munich, Germany, with subsidiaries in Oxford, UK and San Diego, USA. MediGene is the first German biotech company to have drugs on the market, which are being distributed by partner companies.

### Contact MediGene AG

E-mail: [investor@medigene.com](mailto:investor@medigene.com)

Fax: ++49 - 89 - 85 65 - 2920

Julia Hofmann / Dr. Georg Dönges, Public Relations, Tel.: ++49 - 89 - 85 65 - 3317

Dr. Michael Nettersheim / Dr. Georg Dönges, Investor Relations, Tel.: ++49 - 89 - 85 65 - 2946